David Doherty Sells 8,867 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CFO David Doherty sold 8,867 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $12.50, for a total transaction of $110,837.50. Following the transaction, the chief financial officer directly owned 221,679 shares in the company, valued at $2,770,987.50. The trade was a 3.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Surgery Partners Price Performance

Shares of NASDAQ:SGRY opened at $12.65 on Wednesday. Surgery Partners, Inc. has a one year low of $12.25 and a one year high of $24.60. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -20.40 and a beta of 1.95. The company has a 50-day simple moving average of $14.83 and a 200-day simple moving average of $17.57. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.44 EPS. On average, analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Surgery Partners announced that its board has approved a stock buyback plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 9.7% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Board authorizes $200M share repurchase (up to ~9.7% of shares), which can support the share price and signals management believes shares are undervalued. Buyback Announcement
• Positive Sentiment: Analyst coverage skews bullish — multiple firms (UBS, Jefferies, Cantor Fitzgerald, Benchmark) have buy/overweight views and the consensus price target (~$23.36) is well above the current price, which supports upside expectations. Analyst Notes
• Positive Sentiment: Large institutional investors have been increasing stakes (Janus Henderson, Pentwater, UBS, Vanguard), showing continued institutional confidence/interest in the stock. Institutional Ownership
• Neutral Sentiment: Q4 results: revenue of $885M beat estimates (~$866.5M) and rose 2.4% year-over-year, which is supportive for top-line trend, but the quarter included a sizable EPS miss. Earnings Report
• Negative Sentiment: CEO Jason Eric Evans sold 20,400 shares at ~$12.47 (≈$254K), a ~2.17% reduction in his holding — a high-profile insider sale that can weigh on investor confidence. Form 4 CEO Sale
• Negative Sentiment: CFO David T. Doherty sold 8,867 shares at ~$12.50 (~$110.8K), trimming his stake by ~3.85%, which may raise governance/sentiment questions. Form 4 CFO Sale
• Negative Sentiment: Other insiders (Jennifer Baldock, Marissa Brittenham, Danielle Burkhalter) executed sales in mid‑March (ranging ~3.5k–5.8k shares each), adding to near-term selling pressure. Insider Trades Summary

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Pentwater Capital Management LP lifted its holdings in Surgery Partners by 66.9% in the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after acquiring an additional 4,681,000 shares during the period. UBS Group AG grew its stake in shares of Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after purchasing an additional 4,113,052 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Surgery Partners by 528.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after purchasing an additional 1,647,714 shares during the period. Glenview Capital Management LLC purchased a new position in shares of Surgery Partners in the 2nd quarter valued at about $33,995,000. Finally, King Street Capital Management L.P. increased its holdings in shares of Surgery Partners by 24.5% in the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock valued at $138,382,000 after purchasing an additional 1,225,000 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Barclays dropped their target price on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 3rd. Benchmark reiterated a “buy” rating on shares of Surgery Partners in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. cut their price objective on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Surgery Partners currently has an average rating of “Moderate Buy” and an average target price of $23.36.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.